| Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy (NCT05833438) | University of Leipzig | 2023-05-17 |
| Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer (NCT06451211) | Sun Yat-sen University | 2023-05-17 |
| Ritlecitinib in CTCL (NCT05879458) | Icahn School of Medicine at Mount Sinai | 2023-05-17 |
| Mindfulness-oriented Recovery Enhancement (MORE) for Cancer Pain Relief (NCT05877521) | Memorial Sloan Kettering Cancer Center | 2023-05-16 |
| Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia (NCT05852847) | Peking University People's Hospital | 2023-05-16 |
| A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB) (NCT05673928) | M.D. Anderson Cancer Center | 2023-05-16 |
| Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer (NCT05882513) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2023-05-16 |
| Patient-centered and Neurocognitive Outcomes With Acetazolamide for Sleep Apnea (NCT05804084) | University of California, San Diego | 2023-05-16 |
| A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes (NCT05791201) | Vertex Pharmaceuticals Incorporated | 2023-05-16 |
| BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors (NCT05869240) | Betta Pharmaceuticals Co., Ltd. | 2023-05-16 |
| Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05) (NCT05823987) | Fudan University | 2023-05-16 |
| Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuations (NCT06614153) | Jiangsu HengRui Medicine Co., Ltd. | 2023-05-16 |
| PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung (NCT05553834) | Duke University | 2023-05-16 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC (NCT05670106) | Novartis Pharmaceuticals | 2023-05-16 |
| Safety and Efficacy of Faricimab in Patients With NPDR (NCT05681884) | Greater Houston Retina Research | 2023-05-16 |
| A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) (NCT05319730) | Merck Sharp & Dohme LLC | 2023-05-16 |
| A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations (NCT05588141) | National Cancer Institute (NCI) | 2023-05-16 |
| FMT in IT-refractory HCC - FAB-HCC Pilot Study (NCT05750030) | Medical University of Vienna | 2023-05-16 |
| Safety, Feasibility, and Tolerability of Sulforaphane in Children with Chronic Kidney Disease (NCT05653492) | University of Rochester | 2023-05-15 |
| A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease (NCT05424276) | ABLi Therapeutics, Inc. | 2023-05-15 |
| A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1) (NCT05230459) | AskBio Inc | 2023-05-15 |
| Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis (NCT05671835) | Tvardi Therapeutics, Incorporated | 2023-05-15 |
| Using Hydrating Cream to Improve Repeated Hand Skin Injury Among Tug-of-war Players (NCT05861713) | Chang Gung Memorial Hospital | 2023-05-15 |
| A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease (NCT05907668) | Immunovant Sciences GmbH | 2023-05-15 |
| Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (NCT05538091) | Ronald Buckanovich | 2023-05-15 |
| A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC (NCT05837052) | Zhejiang University | 2023-05-15 |
| Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer (NCT05866510) | Peking University | 2023-05-15 |
| Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia (NCT05881265) | Shanghai Jiao Tong University School of Medicine | 2023-05-15 |
| A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC (NCT05896059) | Zhejiang Cancer Hospital | 2023-05-15 |
| A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection (NCT05729568) | Gilead Sciences | 2023-05-15 |
| Fluvoxamine for Long COVID-19 (NCT05874037) | Washington University School of Medicine | 2023-05-15 |
| OSIG-eye Drops Treatment for Dry Eye Disease (NCT04510428) | University of Illinois at Chicago | 2023-05-15 |
| Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia (NCT05890794) | AM-Pharma | 2023-05-15 |
| A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age (NCT05903183) | Icosavax, Inc. | 2023-05-15 |
| Decitabine and Anti-PD-1 in R/R DLBCL (NCT05816746) | Chinese PLA General Hospital | 2023-05-15 |
| Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA Vaccine Candidate Variations in Healthy Adults (NCT05868382) | ModernaTX, Inc. | 2023-05-15 |
| A Multicenter, Phase 2 Study Evaluating the Value of Radiotherapy in Advanced Diffuse Large B-cell Lymphoma Patients With Extranodal Involvement and Large Tumors Undergoing Immunochemotherapy for PET-CT Assessment of Complete Remission (NCT05874778) | Tianjin Medical University Cancer Institute and Hospital | 2023-05-15 |
| Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism (NCT05823012) | Xeris Pharmaceuticals | 2023-05-15 |
| Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial (NCT05763992) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2023-05-15 |
| Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities (NCT05808322) | National Taiwan University Hospital | 2023-05-15 |
| Prospective Study of Particle Radiotherapy for Breast Cancer With Different Arm Position (NCT05878678) | Shanghai Proton and Heavy Ion Center | 2023-05-15 |
| A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma (NCT05765812) | Debiopharm International SA | 2023-05-15 |
| Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases (NCT05807893) | Sun Yat-sen University | 2023-05-14 |
| A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (NCT05712356) | Lisata Therapeutics, Inc. | 2023-05-13 |
| Reduced-dose Botox for Urgency Incontinence Among Elder Females (NCT05512039) | Dartmouth-Hitchcock Medical Center | 2023-05-12 |
| PembROlizumab With or Without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (NCT05743777) | Canadian Cancer Trials Group | 2023-05-12 |
| DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors (NCT05684276) | Fundación GECP | 2023-05-12 |
| A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC) (NCT05851924) | Memorial Sloan Kettering Cancer Center | 2023-05-12 |
| To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer (NCT05673512) | SUNHO（China）BioPharmaceutical CO., Ltd. | 2023-05-12 |
| Phase II Trial of Lung Chemoemobolization (NCT05672108) | City of Hope Medical Center | 2023-05-12 |
| XKH001 Injection in Healthy Subjects (NCT05991661) | Beijing Kanova Biopharmaceutical Co., LTD | 2023-05-12 |
| First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT) (NCT05749900) | Yonsei University | 2023-05-12 |
| Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy (NCT05672316) | City of Hope Medical Center | 2023-05-11 |
| Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (NCT05845450) | Gruppo Oncologico del Nord-Ovest | 2023-05-11 |
| LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer (NCT05886439) | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-05-11 |
| An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) (NCT05649722) | Insmed Incorporated | 2023-05-11 |
| HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC (NCT06335927) | Fudan University | 2023-05-11 |
| OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED) (NCT05814757) | Ocular Therapeutix, Inc. | 2023-05-11 |
| Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal Adenocarcinoma (NCT05858567) | Sir Run Run Shaw Hospital | 2023-05-11 |
| XTX301 in Patients With Advanced Solid Tumors (NCT05684965) | Xilio Development, Inc. | 2023-05-11 |
| Inguinal Node Sparing Radiotherapy For Patients With Early Stage Anal Cancer (NCT05040815) | AHS Cancer Control Alberta | 2023-05-11 |
| MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies (NCT05735717) | Masonic Cancer Center, University of Minnesota | 2023-05-11 |
| A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer (NCT06000917) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2023-05-11 |
| Study of LW402 in Moderate-to-Severe Atopic Dermatitis (NCT07186387) | Shanghai Longwood Biopharmaceuticals Co., Ltd. | 2023-05-11 |
| A Study of Danavorexton in People With Obstructive Sleep Apnea After General Anesthesia for Abdominal Surgery (NCT05814016) | Takeda | 2023-05-11 |
| Caplyta in Borderline Personality Disorder (NCT05356013) | University of Chicago | 2023-05-10 |
| Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer (NCT05824468) | Sun Yat-sen University | 2023-05-10 |
| Immunogenicity and Safety of the Concomitant Administration of OVX836 Influenza Vaccine, Quadrivalent Inactivated Influenza Vaccines and Placebo in Healthy Subjects. (NCT05734040) | Osivax | 2023-05-10 |
| Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases (NCT06416709) | Cell Energy Life Sciences Group Co. LTD | 2023-05-10 |
| Colo-Pro_2: Bolus-continuous Infusion Cefuroxime Prophylaxis for the Prevention of Infections After Colorectal Surgery (NCT05609240) | University of Leeds | 2023-05-10 |
| Safety and Efficacy of Atorvastatin v. Placebo on HCC Risk (NCT05028829) | Raymond Chung | 2023-05-10 |
| Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. (NCT05295680) | Aparna Goel | 2023-05-10 |
| A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection (NCT05612581) | Vir Biotechnology, Inc. | 2023-05-10 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) (NCT05836779) | Caliway Biopharmaceuticals Co., Ltd. | 2023-05-10 |
| Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer (NCT05699655) | Fujian Cancer Hospital | 2023-05-10 |
| Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial (NCT05710328) | ECOG-ACRIN Cancer Research Group | 2023-05-10 |
| An Open-Label Study Evaluating Brexanolone in Adults With Tinnitus (NCT05645432) | Supernus Pharmaceuticals, Inc. | 2023-05-10 |
| Study to Evaluate the Safety and Efficacy of ESC-derived Dopamine Progenitor Cell Therapy in PD Patients (NCT05887466) | S.Biomedics Co., Ltd. | 2023-05-09 |
| A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies (NCT05588440) | Oncternal Therapeutics, Inc | 2023-05-09 |
| Phase II Cohort of Spinal Stereotactic Radiotherapy in Patients Using a MR LINAC (NCT05709782) | M.D. Anderson Cancer Center | 2023-05-09 |
| Controlled Trial of Omadacycline Randomized Treatment Given for Bone and Joint Infection (NCT05753215) | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | 2023-05-09 |
| Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer (NCT05501665) | Vanderbilt-Ingram Cancer Center | 2023-05-09 |
| Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer (NCT05462613) | Centre Hospitalier Universitaire de Besancon | 2023-05-09 |
| Triphala Supplementation and High-intensity Interval Exercise and Immune System Function and Oxidative Stress (NCT06208761) | Burapha University | 2023-05-09 |
| Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC (NCT05982834) | Fudan University | 2023-05-09 |
| Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors (NCT05764395) | Vanderbilt-Ingram Cancer Center | 2023-05-09 |
| A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain (NCT05892068) | Memorial Sloan Kettering Cancer Center | 2023-05-09 |
| Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma (NCT05826535) | Lyell Immunopharma, Inc. | 2023-05-09 |
| Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer (NCT06136910) | Fujian Cancer Hospital | 2023-05-09 |
| Safety and Suitability of Supplementing Early MIP Surgery (MIPS) of ICH With Pioglitazone (NCT05582707) | University of Maryland, Baltimore | 2023-05-08 |
| Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer (NCT05824481) | Sun Yat-sen University | 2023-05-08 |
| Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies (NCT05039632) | M.D. Anderson Cancer Center | 2023-05-08 |
| Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial (NCT05862168) | Weijia Fang, MD | 2023-05-08 |
| A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer (NCT05846867) | Akeso | 2023-05-08 |
| VE202 in Patients With Mild-to-Moderate Ulcerative Colitis (NCT05370885) | Vedanta Biosciences, Inc. | 2023-05-08 |
| Effects of Pazopanib on Hereditary Hemorrhagic Telangiectasia Related Epistaxis and Anemia (Paz) (NCT03850964) | Cure HHT | 2023-05-08 |
| Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure (NCT06334757) | Henan Cancer Hospital | 2023-05-08 |
| Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy (NCT05775042) | Keymed Biosciences Co.Ltd | 2023-05-08 |
| Pharmacokinetic Study of Minocycline in Patients With Pulmonary Nontuberculous Mycobacterial Disease (NCT05861258) | Radboud University Medical Center | 2023-05-08 |
| Clinical Therapeutic Potential of Novel Microbiome LP-51 on Xerosis Individual Based on Xerosis-microbiome Index (NCT06706050) | Ho-Yeon Song | 2023-05-08 |